Digital Life Coaching for Myeloma Patients Undergoing Transplantation

Multiple Myeloma Clinical Trial

Official title:

Digital Life Coaching in Multiple Myeloma Patients Undergoing Hematopoietic Stem Cell Transplantation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04432818
• Other study ID #: 20252
• Secondary ID: NCI-2020-04166
• Status: Completed
• Phase: N/A
• Start date: May 20, 2020
• Est. completion date: February 25, 2021

Study information

• Verified date: June 2021
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is the first study of digital life coaching (DLC) to engage patients during the peri-HCT period that is punctuated by intensive life changes. DLC may circumvent these limitations by combining the integrative cross-dimensional nature of life coaching with the advantages of mobile health technology. The purpose of this study is to evaluate whether ongoing participant engagement with a DLC platform is feasible for multiple myeloma (MM) patients actively undergoing hematopoietic stem cell transplantation (HCT).

Description:

Participants will receive unlimited access to Pack Health's DLC platform during a 16-week period encompassing pre-HCT conditioning chemotherapy, post-HCT recovery, and 100-day follow-up. Participants will engage with Pack Health's DLC platform and complete quality of life assessments for 16 weeks beginning from enrollment. At the conclusion of the treatment period, participants will be asked to rate their satisfaction with the DLC platform Primary Objective: To evaluate the rate of ongoing participant engagement with a DLC platform during the study period Secondary Objectives: - To assess quality of life among participants during the study period - To assess psychosocial distress among participants during the study period - To assess sleep disturbances among participants during the study period - To assess participant satisfaction with the DLC platform at the end of the study period Exploratory Objectives: - To assess benzodiazepine and zolpidem-class drug usage for anxiety or insomnia among participants during the study period - To assess communications with treatment teams among participants during the study period - To assess 100-day clinical outcomes among participants at the end of the study period

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: February 25, 2021
• Est. primary completion date: February 25, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Confirmed diagnosis of one of the following (all referred to as MM in this protocol):
• Multiple myeloma (ICD-10 code: C90.0)
• Extramedullary plasmacytoma (ICD-10 code: C90.2)
• Planned receipt of autologous HCT at our institution
• Patients undergoing outpatient HCT will be eligible
• Patients who received chemomobilization will be eligible
• Age = 18, as life coaches employed by the DLC vendor are not currently trained to work with pediatric patients

Exclusion Criteria:

• Prior autologous HCT for any indication
• Physician-assessed lack of sufficient English proficiency
• Lack of ownership of a personal smartphone
• Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with participant's safety, provision of informed consent, or compliance with study procedures

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Behavioral:
• Pack Health's digital life coaching (DLC)
Pack Health smartphone-based DLC platform will be provided for 16-week subscription which allows unlimited bidirectional communication between enrolled participants and their life coach

Locations

Country	Name	City	State
United States	University of California, San Francisco	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants displaying ongoing engagement with DLC	Ongoing participant engagement is defined as at least 4 or more participant-initiated interactions with the DLC platform, including at least 1 interaction in each of four 4-week study sub-periods	Up to 16 weeks
Secondary	Median PRO Measurement Information System (PROMIS) Global Health (GH) Score	The PROMIS GH instrument v1.2 will be used to assess quality of life. This 10-item inventory with scores ranging from 1 to 5 with higher scores indicating a a greater quality of life. Raw PROMIS scores will subsequently be transformed to T-score metrics as per the scoring manual to reflect a population mean of 50 and standard deviation of 10. Among cancer patients, a T-score change of 5 points on any PROMIS inventory is generally considered to be clinically meaningful.	Up to 16 weeks
Secondary	Median National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT) Score	The NCCN DT will be used to assess psychosocial distress. This single-item inventory uses a graphic of a thermometer to allow patients to assess their overall distress on a scale of 0=No Distress to 10= Extreme distress. The NCCN considers a cutoff score of 4 to differentiate clinically significant distress.	Up to 16 weeks
Secondary	Median PROMIS Sleep Disturbance (SD) Short Form (SF) 4a Score	The PROMIS SD SF 4a inventory will be used to measure overall sleep disturbance in past 7 days. This assessment consists of 4 items which measure sleep quality and sleep disturbances using a 5 point likert scale ranging in value from 1 to 5 with higher scores indicating greater sleep quality. Raw PROMIS scores will subsequently be transformed to T-score metrics as per the scoring manual to reflect a population mean of 50 and standard deviation of 10. Among cancer patients, a T-score change of 5 points on any PROMIS inventory is generally considered to be clinically meaningful	Up to 16 weeks
Secondary	Median Participant Satisfaction Score	Participants will be asked to provide a response, on a scale from 0 (not at all likely) to 10 (extremely likely), to the following single question: "How likely are you to recommend this life coaching tool to other patients undergoing stem cell transplantation?"	Up to 16 weeks